Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated:  9/28/2017
MAAS
mi
from
New Haven, CT
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated: 9/28/2017
MAAS
mi
from
New Haven, CT
Click here to add this to my saved trials
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated:  9/28/2017
Hispanic Clinic
mi
from
New Haven, CT
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated: 9/28/2017
Hispanic Clinic
mi
from
New Haven, CT
Click here to add this to my saved trials
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated:  9/28/2017
Substance Abuse Treatment Unit (SATU)
mi
from
New Haven, CT
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated: 9/28/2017
Substance Abuse Treatment Unit (SATU)
mi
from
New Haven, CT
Click here to add this to my saved trials
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated:  9/28/2017
Fair Haven Community Health
mi
from
New Haven, CT
CBT for Spanish Speakers
Computer Based Training in CBT for Spanish-speaking Substance Users
Status: Enrolling
Updated: 9/28/2017
Fair Haven Community Health
mi
from
New Haven, CT
Click here to add this to my saved trials
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
Status: Enrolling
Updated:  10/2/2017
University of Florida, Institute for Child Health Policy
mi
from
Gainesville, FL
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
Status: Enrolling
Updated: 10/2/2017
University of Florida, Institute for Child Health Policy
mi
from
Gainesville, FL
Click here to add this to my saved trials
Using Mobile Technology to Enhance Early Psychosis Treatment Delivery
Using Mobile Technology To Detect Early Warning Signs of Mental Health Challenges and Enhance Treatment Delivery For Youth
Status: Enrolling
Updated:  10/2/2017
UC Davis Imaging Research Center
mi
from
Sacramento, CA
Using Mobile Technology to Enhance Early Psychosis Treatment Delivery
Using Mobile Technology To Detect Early Warning Signs of Mental Health Challenges and Enhance Treatment Delivery For Youth
Status: Enrolling
Updated: 10/2/2017
UC Davis Imaging Research Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Insulin Resistance in Patients With Major Depression
Insulin Resistance in Patients With Major Depression
Status: Enrolling
Updated:  10/3/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Insulin Resistance in Patients With Major Depression
Insulin Resistance in Patients With Major Depression
Status: Enrolling
Updated: 10/3/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Status: Enrolling
Updated:  10/3/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Status: Enrolling
Updated: 10/3/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa
Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa
Status: Enrolling
Updated:  10/3/2017
Stanford University
mi
from
Stanford, CA
Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa
Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa
Status: Enrolling
Updated: 10/3/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Melatonin and Sleep in Preventing Delirium in the Hospital
Melatonin and Sleep in Preventing Delirium in the Hospital: A Randomized Placebo-controlled Trial
Status: Enrolling
Updated:  10/3/2017
Scripps Green Hospital
mi
from
La Jolla, CA
Melatonin and Sleep in Preventing Delirium in the Hospital
Melatonin and Sleep in Preventing Delirium in the Hospital: A Randomized Placebo-controlled Trial
Status: Enrolling
Updated: 10/3/2017
Scripps Green Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Memorial Hospital Central
mi
from
Colorado Springs, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Memorial Hospital Central
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Memorial Hospital North
mi
from
Colorado Springs, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Memorial Hospital North
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Denver Health Medical Center, Medical ICU
mi
from
Denver, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Denver Health Medical Center, Medical ICU
mi
from
Denver, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Porter Adventist Hospital
mi
from
Denver, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
St. Anthony Hospital
mi
from
Lakewood, CO
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
St. Anthony Hospital
mi
from
Lakewood, CO
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Louisiana State University
mi
from
New Orleans, LA
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Louisiana State University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated:  10/4/2017
Ben Taub Hospital
mi
from
Houston, TX
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
Status: Enrolling
Updated: 10/4/2017
Ben Taub Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression
Safety and Efficacy of Open Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression
Status: Enrolling
Updated:  10/4/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression
Safety and Efficacy of Open Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression
Status: Enrolling
Updated: 10/4/2017
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Parents at the Center: Information Management in ADHD - Clinical Trial
Parents at the Center: Information Management in ADHD - Clinical Trial
Status: Enrolling
Updated:  10/4/2017
Children's Hospital Boston
mi
from
Boston, MA
Parents at the Center: Information Management in ADHD - Clinical Trial
Parents at the Center: Information Management in ADHD - Clinical Trial
Status: Enrolling
Updated: 10/4/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Effects of Sertraline on Brain Connectivity in Adolescents With OCD
Effects of Sertraline on Brain Connectivity in Adolescents With OCD (Obsessive-Compulsive Disorder)
Status: Enrolling
Updated:  10/4/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Effects of Sertraline on Brain Connectivity in Adolescents With OCD
Effects of Sertraline on Brain Connectivity in Adolescents With OCD (Obsessive-Compulsive Disorder)
Status: Enrolling
Updated: 10/4/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Genetics of Obsessive-Compulsive Disorder
Genetics of Obsessive-Compulsive Disorder: A Collaborative Study
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Genetics of Obsessive-Compulsive Disorder
Genetics of Obsessive-Compulsive Disorder: A Collaborative Study
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Screening Evaluation for NIAAA Protocols
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Screening Evaluation for NIAAA Protocols
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Examination of Brain Serotonin Receptors in Patients With Mood Disorders
Serotonin1A Receptor and Serotonin Transporter Imaging In Mood Disorders
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Examination of Brain Serotonin Receptors in Patients With Mood Disorders
Serotonin1A Receptor and Serotonin Transporter Imaging In Mood Disorders
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Social Emotional Information and Instrumental Learning
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning
Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Social Emotional Information and Instrumental Learning
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Body Weight Regulation in Patients With Narcolepsy
The Role of the Orexin System in Body Weight Regulation: Patients With Narcolepsy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Body Weight Regulation in Patients With Narcolepsy
The Role of the Orexin System in Body Weight Regulation: Patients With Narcolepsy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical and Immunological Investigations of Subtypes of Autism
Clinical and Immunological Investigations of Subtypes of Autism
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Clinical and Immunological Investigations of Subtypes of Autism
Clinical and Immunological Investigations of Subtypes of Autism
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Eating Behavior in Adolescents
Eating Behavior in Adolescents
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Eating Behavior in Adolescents
Eating Behavior in Adolescents
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Identification of Characteristics Associated With Symptom Remission in Autism
Characterization of Autism Spectrum Disorder in School Aged Children
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Identification of Characteristics Associated With Symptom Remission in Autism
Characterization of Autism Spectrum Disorder in School Aged Children
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain Glutamate Receptors and Cocaine Dependence
Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving
Status: Enrolling
Updated:  10/5/2017
National Institute on Drug Abuse, Biomedical Research Center
mi
from
Baltimore, MD
Brain Glutamate Receptors and Cocaine Dependence
Cocaine Dependence, Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Density, Genetics and Craving
Status: Enrolling
Updated: 10/5/2017
National Institute on Drug Abuse, Biomedical Research Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cholesterol in ASD: Characterization and Treatment
Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cholesterol in ASD: Characterization and Treatment
Cholesterol in Autism Spectrum Disorder (ASD): Characterization and Treatment
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
A Magnetic Resonance Spectroscopic Examination of Children and Adolescents Taking Riluzole for Obsessive-Compulsive Disorder
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clarithromycin for the Treatment of Hypersomnia
Clarithromycin for the Treatment of Hypersomnia
Status: Enrolling
Updated:  10/5/2017
Emory Sleep Center
mi
from
Atlanta, GA
Clarithromycin for the Treatment of Hypersomnia
Clarithromycin for the Treatment of Hypersomnia
Status: Enrolling
Updated: 10/5/2017
Emory Sleep Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Status: Enrolling
Updated:  10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders
Status: Enrolling
Updated: 10/5/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Status: Enrolling
Updated:  10/5/2017
Walter Reed National Military Medical Center (WRNMMC)
mi
from
Bethesda, MD
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Status: Enrolling
Updated: 10/5/2017
Walter Reed National Military Medical Center (WRNMMC)
mi
from
Bethesda, MD
Click here to add this to my saved trials
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Status: Enrolling
Updated:  10/5/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Study to Identify the Genetic Variations Associated With Phantom Limb Pain
Status: Enrolling
Updated: 10/5/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Screening for Childhood-Onset Psychotic Disorders
Screening, Evaluation, Diagnosis, Treatment Optimization and Follow-up for Childhood Onset Psychotic Disorders
Status: Enrolling
Updated:  10/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Screening for Childhood-Onset Psychotic Disorders
Screening, Evaluation, Diagnosis, Treatment Optimization and Follow-up for Childhood Onset Psychotic Disorders
Status: Enrolling
Updated: 10/6/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders
Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders
Status: Enrolling
Updated:  10/6/2017
Center for Anxiety and Related Disorders, Boston University
mi
from
Boston, MA
Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders
Efficacy Evaluation of a Unified Transdiagnostic Treatment for Anxiety Disorders
Status: Enrolling
Updated: 10/6/2017
Center for Anxiety and Related Disorders, Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Charleston, SC
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Anaheim, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Carson, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Carson, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Colton, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Colton, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Costa Mesa, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Downey, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Glendale, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Glendale, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
National City, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
National City, CA
Click here to add this to my saved trials
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated:  10/9/2017
Clinical Research Facility
mi
from
Oceanside, CA
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Status: Enrolling
Updated: 10/9/2017
Clinical Research Facility
mi
from
Oceanside, CA
Click here to add this to my saved trials